Head-to-head evidence
BGM0504 vs tirzepatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
BGM0504
Developed by BrightGene Bio-Medical Technology
NCT06973681 · Phase 2 · completed
The study was randomized and double-blind, with three BGM0504 dose groups and a placebo comparator, and enrolled 120 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07658560 (registry estimate)
tirzepatide · Zepbound / Mounjaro
Marketed by Eli Lilly
NCT04184622 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial in 2,539 participants using percent change in body weight, the disease-defining endpoint for obesity, as the primary measure. All three tirzepatide doses produced significantly greater weight loss than placebo at 72 weeks.
Next expected readout: November 2026 · NCT07299084 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BGM0504's landscape · tirzepatide's landscape